A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
Kura Oncology, Inc.
Incyte Corporation
Nammi Therapeutics Inc
Compass Therapeutics
Exscientia AI Limited
KaliVir Immunotherapeutics
Bristol-Myers Squibb
AstraZeneca
Arcus Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Exelixis
Neomorph, Inc
Xencor, Inc.
Jonsson Comprehensive Cancer Center
ViroMissile, Inc.
City of Hope Medical Center
Tizona Therapeutics, Inc
Shanghai Henlius Biotech
Deciphera Pharmaceuticals, LLC
MacroGenics
SAPU NANO (US) LLC
HiberCell, Inc.
M.D. Anderson Cancer Center
Calico Life Sciences LLC
Sairopa B.V.
University of Texas Southwestern Medical Center
LG Chem
St. Jude Children's Research Hospital
Janux Therapeutics
Chongqing Precision Biotech Co., Ltd
Novelty Nobility, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, San Francisco
Zhejiang University
Shanghai Junshi Bioscience Co., Ltd.
University of California, Davis
LaunXP Biomedical Co., Ltd.
University Hospital of Split
Molecure S.A.
Osel, Inc.
Chongqing Precision Biotech Co., Ltd